百心安-B(2185.HK)今日正式登陸港交所
格隆匯12月23日丨百心安-B(2185.HK)今日正式在港交所掛牌上市,該股發行價為21.25港元,市值超50億港元。百心安成立於2014年,是中國領先的創新介入式心血管裝置公司。目前,百心安專注於以下兩種療法:1)全降解支架(BRS)療法,以解決患者在治療冠狀及外周動脈疾病方面的醫療需求;2)腎神經阻斷(RDN)療法,以解決患者在治療未控高血壓及頑固性高血壓方面的醫療需求。據悉,全降解支架療法是使用聚合物臨時支架使冠狀動脈在一段時間內被支撐的手術,而支架本身會在人體內逐漸被良性吸收。全降解支架引入“介入無植入”的理念,有潛力改變介入式心臟病傳統的治療模式。腎神經阻斷屬於低侵入性手術,利用射頻消融破壞腎動脈的神經,起到降低血壓的作用,而不會使動脈受損。百心安在研產品第二代Iberis預期將成為中國首款獲批的多電極腎神經阻斷產品,並有潛力為革命性地治療高血壓的醫療器械領域提供更多選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.